Virafin for moderate Covid 19

April 26, 2021

The Drugs Controller General of India (DGCI) on Friday approved the emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b ‘Virafin’ for treating moderate COVID-19 infection for adults. Zydus Cadila announced that it has received emergency use approval from DCGI to use Virafin for the treatment of moderate COVID-19 infections. As per the report, a single-dose subcutaneous regimen of the drug will make the treatment of COVID-19 more convenient. The company had said that if administered early on during COVID-19, Virafin may help patients recover faster and avoid much of the complications. It will be available on the prescription of a medical specialist.

Virafin for moderate Covid 19

RELATED NEWS

15 found guilty in Sri Lanka Easter Sunday attacks trial

Supreme Court says 22nd Amendment does not require referendum

When an oil shock reaches Sri Lanka

Around 150 Cabinet decisions aligned with NPP manifesto, PAFFREL says

15 found guilty in Sri Lanka Easter Sunday attacks trial

Supreme Court says 22nd Amendment does not require referendum

When an oil shock reaches Sri Lanka

Around 150 Cabinet decisions aligned with NPP manifesto, PAFFREL says

Government plans to increase funding for school sports development

Government plans to increase funding for school sports development

Chandrabandara advances to Asian Games boxing round of 16

More than 1,600 people affected by severe weather across Sri Lanka

Extra security deployed at Colombo court ahead of Easter Sunday attacks verdict